Articles – Generic Peptides

Explore research-focused peptide articles designed to make complex compounds, safety considerations, and emerging peptide science easier to understand.

Tirzepatide: Dual GIP/GLP-1 Agonist With Superior Weight Loss Data

Tirzepatide (Mounjaro / Zepbound): The First-in-Class Dual GIP/GLP-1 Receptor Agonist With FDA-Approved T2DM, Obesity, and Sleep Apnea Indications and Superior Weight Loss to Semaglutide in 2025 SURMOUNT-5 By Medical Team of Generic Peptides Tirzepatide (LY32…

Tesamorelin Peptide: What the Research Shows (2026)

Tesamorelin Peptide: What the Research Shows (2026) By Medical Team of Generic Peptides Quick answer. Tesamorelin is a synthetic 44-amino-acid analog of growth hormone–releasing hormone (GHRH). A small chemical modification at its N-terminus makes it resistan…

Somatropin vs GH Peptides: What the Research Shows

Somatropin vs GH Secretagogues: What the Research Shows By Medical Team of Generic Peptides Somatropin is the recombinant form of human growth hormone (hGH). It is often grouped with "growth hormone peptides" such as sermorelin and ipamorelin, but it is a dif…

Is Sermorelin FDA Approved? 503A Status Explained

Sermorelin: What It Is, What the Research Shows, and Its FDA Status By Medical Team of Generic Peptides Quick answer. Sermorelin is a synthetic copy of the first 29 amino acids of human growth hormone–releasing hormone (GHRH 1-29). It was FDA-approved under t…

Semax: What the Research Shows (2026)

Semax: What the Research Shows (2026) By Medical Team of Generic Peptides Quick answer. Semax is a synthetic seven-amino-acid peptide built on a fragment of adrenocorticotropic hormone, ACTH(4-7), with a Pro-Gly-Pro tail added for stability. It was developed …

Semaglutide: Ozempic/Wegovy GLP-1 Agonist With 2025 MASH Approval

Semaglutide (Ozempic, Wegovy, Rybelsus): The FDA-Approved GLP-1 Receptor Agonist With Multiple Indications, Robust Phase 3 Evidence, and 2025 MASH Approval By Medical Team of Generic Peptides Semaglutide is a synthetic 31-amino-acid GLP-1 receptor agonist ana…